BTK and B-cell chronic lymphocytic leukemia: As a novel agent approved for BCM treatment, BTK inhibitors were proven to have high efficacy for the treatment of haematological malignancies, such as CLL, WM, MCL, and MZL, as well as chronic graft-versus-host disease (Zelenetz et al., 2019; Wierda et al., 2020).